Literature DB >> 8695060

SPECT imaging of dopamine receptors with [123I]epidepride: characterization of uptake in the human brain.

J Kornhuber1, T Brücke, P Angelberger, S Asenbaum, I Podreka.   

Abstract

[123I]Epidepride is a new ligand for single photon emission computerized tomography (SPECT) that specifically labels D2-like dopamine receptors with very high affinity. Here, we report on the regional kinetic uptake of [123I]epidepride in the brain of 4 normal volunteers and 3 patients with choreatic movement disorders. In healthy subjects striatal activity peaked at 2.5 hours after injection of the tracer and decreased slowly thereafter. There were no significant differences between left and right brain hemispheres. Activity above background was also measurable in areas corresponding to the thalamus, temporal cortex and frontal cortex. The striatal to cerebellar ratio was about 14 after 2.5 hours and this ratio steadily increased with time. The striatal to cerebellar ratio was clearly reduced in all 3 patients with choreatic movement disorders (from about 14 in control subjects after 2.5 hours to about 7 in choreatic patients). [123I]Epidepride may be a useful SPECT ligand for studying D2 receptors in the living human brain because of its high target to background ratio, its high affinity and the possibility to investigate extrastriatal D2 receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8695060     DOI: 10.1007/bf01271548

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  24 in total

1.  Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain.

Authors:  J N Joyce; A Janowsky; K A Neve
Journal:  J Pharmacol Exp Ther       Date:  1991-06       Impact factor: 4.030

2.  Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.

Authors:  T Brücke; I Podreka; P Angelberger; S Wenger; A Topitz; B Küfferle; C Müller; L Deecke
Journal:  J Cereb Blood Flow Metab       Date:  1991-03       Impact factor: 6.200

3.  Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride.

Authors:  R M Kessler; W O Whetsell; M S Ansari; J R Votaw; T de Paulis; J A Clanton; D E Schmidt; N S Mason; R G Manning
Journal:  Brain Res       Date:  1993-04-23       Impact factor: 3.252

4.  The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy.

Authors:  D M Mann; R Oliver; J S Snowden
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

5.  High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain.

Authors:  R M Kessler; J R Votaw; D E Schmidt; M S Ansari; K P Holdeman; T de Paulis; J A Clanton; R Pfeffer; R G Manning; M H Ebert
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

6.  Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients.

Authors:  J L Martinot; P Peron-Magnan; J D Huret; B Mazoyer; J C Baron; J P Boulenger; C Loc'h; B Maziere; V Caillard; H Loo
Journal:  Am J Psychiatry       Date:  1990-01       Impact factor: 18.112

7.  Visualization of extrastriatal dopamine D2 receptors in the human brain.

Authors:  R M Kessler; N S Mason; J R Votaw; T De Paulis; J A Clanton; M S Ansari; D E Schmidt; R G Manning; R L Bell
Journal:  Eur J Pharmacol       Date:  1992-11-13       Impact factor: 4.432

8.  Improved delineation of human dopamine receptors using [18F]-N-methylspiroperidol and PET.

Authors:  C D Arnett; A P Wolf; C Y Shiue; J S Fowler; R R MacGregor; D R Christman; M R Smith
Journal:  J Nucl Med       Date:  1986-12       Impact factor: 10.057

9.  High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors.

Authors:  R M Kessler; M S Ansari; D E Schmidt; T de Paulis; J A Clanton; R Innis; M al-Tikriti; R G Manning; D Gillespie
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

10.  In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain.

Authors:  N P Verhoeff; M Bobeldijk; M G Feenstra; G J Boer; M A Maas; E Erdtsieck-Ernste; K de Bruin; E A van Royen
Journal:  Int J Rad Appl Instrum B       Date:  1991
View more
  5 in total

1.  A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.

Authors:  P Tibbo; P H Silverstone; A J McEwan; J Scott; A Joshua; K Golberg
Journal:  J Psychiatry Neurosci       Date:  1997-01       Impact factor: 6.186

2.  In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates.

Authors:  Mark Slifstein; Dah-Ren Hwang; Yiyun Huang; Ningning Guo; Yasuhiko Sudo; Raj Narendran; Peter Talbot; Marc Laruelle
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

3.  Dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity shows striatal dopaminergic dysfunction and response to pallidal stimulation.

Authors:  Inger Marie Skogseid; Oddveig Røsby; Ane Konglund; James P Connelly; Bård Nedregaard; Greg Eigner Jablonski; Nadja Kvernmo; Asbjørg Stray-Pedersen; Joel C Glover
Journal:  J Neurodev Disord       Date:  2018-05-22       Impact factor: 4.025

4.  Effects of the dopamine D2 allosteric modulator, PAOPA, on the expression of GRK2, arrestin-3, ERK1/2, and on receptor internalization.

Authors:  Dipannita Basu; Yuxin Tian; Jayant Bhandari; Jian Ru Jiang; Patricia Hui; Rodney L Johnson; Ram K Mishra
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

5.  Subacute administration of both methcathinone and manganese causes basal ganglia damage in mice resembling that in methcathinone abusers.

Authors:  Andres Asser; Atsuko Hikima; Mari Raki; Kim Bergström; Sarah Rose; Julius Juurmaa; Villem Krispin; Mari Muldmaa; Stella Lilles; Hanna Rätsep; Peter Jenner; Sulev Kõks; Pekka T Männistö; Pille Taba
Journal:  J Neural Transm (Vienna)       Date:  2019-11-30       Impact factor: 3.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.